Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator Oct 1, 2020
Poxel Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-Renal Results at the 56th European Association for the Study of Diabetes Annual Meeting Sep 24, 2020
Poxel to Host Conference Call for First Half 2020 Financial Results on September 15, 2020 Sep 3, 2020
Poxel Announces Submission of Imeglimin Japanese New Drug Application for the Treatment of Type 2 Diabetes by Sumitomo Dainippon Pharma Jul 30, 2020
Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2020 Jul 21, 2020
Poxel Announces Results from June 24, 2020 Ordinary Annual and Extraordinary General Meeting Jun 25, 2020
Poxel Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Results for PXL770, a Direct AMPK Activator for the Treatment of NASH Jun 24, 2020
